***Background.*** Peginterferon lambda-1a (Lambda, Type III IFN) is currently under Phase 3 evaluation as part of combination treatment for HCV infection. The triple regimen of Lambda, daclatasvir (DCV; NS5A inhibitor) and ribavirin (RBV) achieved sustained virologic response (SVR) rates of \>90% in a pilot study of patients chronically infected with genotype 1b HCV when treated for 24 weeks. This triple combination regimen was evaluated for 12 weeks of treatment in a cohort of patients with genotype 1b infection (Study AI452-008c).

***Methods.*** 24 treatment-naive, non-cirrhotic HCV genotype 1b infected patients were treated with open-label Lambda 180 mcg/week + DCV 60mg daily + RBV 1,000-1,200 mg daily for 12 weeks. The primary endpoint is HCV RNA \<LLOQ (25 IU/mL) at 12 weeks post-treatment (SVR12). SVR4 results are reported here with SVR12 available at presentation.

***Results.*** Baseline characteristics were male 46%, Caucasian 96%, and IL28B non-CC genotype 67%. Mean baseline HCV RNA was 6.3 (range 5.1--7.4) log10 IU/mL. SVR4 was achieved in 21/23 (91%) patients with available data. Both patients who did not achieve SVR4 experienced relapse posttreatment. No patients discontinued treatment due to AEs or treatment futility; there were no deaths and no serious AEs. The most frequent AEs were asthenia, pruritus, dry skin and diarrhea. One patient each (n = 3/24) had a Grade 3/4 lab abnormality of elevated ALT/AST, reduced hemoglobin, or increased bilirubin.

                                                Observed       mITT
  --------------------------------------------- -------------- -------------
  HCV RNA \<LLOQ at end of treatment, n/N (%)   24/24 (100)    24/24 (100)
  SVR4, n/N (%)                                 21/23 (91)\*   21/24 (88)
  Post-treatment relapse (n)                    2              

\*1 patient was lost to follow-up (Week 8 undetectable), counted as failure for mITT analysis

***Conclusion.*** 12 weeks of treatment with Lambda + DCV + RBV achieved a high SVR4 rate in treatment-naïve, non-cirrhotic HCV genotype 1b-infected patients. The regimen was generally well tolerated.
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